Chagas disease
Our R&D portfolio for Chagas disease
What we have achieved
We have been active in Chagas research and development, treatment access, and advocacy for more than two decades. Together with our research partners, we helped create the Chagas Clinical Research Platform, a network of over 400 members representing 150 organizations across three continents, to utilize and strengthen R&D capacity in endemic countries.
First-ever treatment for children. With our partners, we developed and registered the first-ever formulations of benznidazole for treating infants and children with Chagas disease.
What we are doing for people living with Chagas disease
Our goal is to make treatment safer, simpler, and more effective. We are also working to improve access to testing and treatment, and develop better tests of cure for treatment monitoring.
Building capacity, uniting expertise
Research platforms and consortiums that bring together researchers and strengthen research capacities in low- and middle-income countries are central to our virtual R&D model.
Partnering for patients
Collaboration is an essential part of how we work. We have forged a diverse range of alliances and research collaborations with over 200 partners in nearly 50 countries.
Making medical history for neglected patients
We develop urgently needed treatments for neglected patients and ensure they’re affordable, available, and adapted to the communities who need them
Stay connected
Get our latest news, personal stories, research articles, and job opportunities.